Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Commercial Supply Remdesivir and Related Intermediates with High Quality Remdesivir CAS 1809249-37-3 2-Ethyl-1-butanol CAS 97-95-0 Trimethylsilyl Cyanide CAS 7677-24-9 4-Nitrophenol CAS 100-02-7 2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate CAS 1911578-98-7 N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester CAS 1354823-36-1 (S)-2-Ethylbutyl 2-Aminopropanoate Hydrochloride CAS 946511-97-3 Remdesivir Metabolite (GS-441524) CAS 1191237-69-0 Remdesivir N-2 Intermediate CAS 1191237-80-5 2,3,5-Tri-O-benzyl-D-ribonolactone CAS 55094-52-5 7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5 Pyrrolo[1,2-F][1,2,4]Triazin-4-Amine CAS 159326-68-8 4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine CAS 1770840-43-1| Item | Specifications |
| Appearance | Light Yellow Powder |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
| Purity | ≥97.0% |
| Loss on Drying | ≤1.0 |
| Single Impurity | ≤1.0% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Remdesivir (CAS 1809249-37-3) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine |
| Synonyms | 4-Amino-7-bromopyrrolo[2,1-f][1,2,4]triazine; Remdesivir Impurity 2 |
| CAS Number | 937046-98-5 |
| CAT Number | RF-PI305 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C6H5BrN4 |
| Molecular Weight | 213.04 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine (CAS 937046-98-5) is an Intermediate of Remdesivir (CAS 1809249-37-3). Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir (also known as Veklury or GS-5734) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. Remdesivir should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Remdesivir was originally developed as an anti-viral against Ebola virus, but since has been shown to attenuate viral loads of a number of RNA viruses including respiratory syncytial virus (RSV) and β-coronaviruses such as SARS-CoV, MERS-CoV, and the causative agent of COVID-19, SARS-CoV-2.
